• Our Company
    • Our story
    • Our vision and strategy
    • Fibrotic lung diseases
    • CEO statement
    • Board of Directors
    • Management
    • Scientific Advisers
    • Contact
    • Work with us
  • Our focus areas
    • Mechanism of Action
    • Severe lung diseases
    • Role of the renin-angiotensin system
    • Role of the AT2 receptor
  • Our programs
    • Pipeline
  • Investors
    • Listing prospectus
    • Overview
    • Press releases
    • The share
      • Share monitor
      • Largest shareholders
      • Share issues
      • Share capital development
      • Analyst coverage
    • Financial reports
    • Financial calendar
    • Events & Presentations
    • Corporate governance
      • General meeting
      • Nomination committeé
      • Board of Directors
      • Audit Committee
      • Remuneration Committee
      • Scientific committee
      • Management
      • Remuneration and incentives
      • Auditors
      • Scientific Advisers
      • Articles of association
    • Image bank
    • Subscribe for press releases
    • Investor Relations contact
  • Investerare (SE)
    • Listningsprospekt
    • Översikt
    • Pressmeddelanden
    • Aktien
      • Aktiekursgraf
      • Största aktieägare
      • Aktiekapitalets utveckling
      • Emissioner
      • Analytiker
    • Finansiella rapporter
    • Finansiell kalender
    • Events & Presentationer
    • Bolagsstyrning
      • Bolagsstämma
      • Valberedning
      • Styrelsen
      • Revisionsutskott
      • Ersättningsutskott
      • Vetenskapligt utskott
      • Ledning
      • Arvoden och ersättningar
      • Revisorer
      • Vetenskapligt råd
      • Bolagsordning
    • Bildbank
    • Prenumerera på nyheter
    • Investerarkontakt
  • Patients and families
    • Disease background
    • Patient story
    • Resources and patient organizations
    • Working with patient groups
    • Access policy
    • Our commitment
logo
  • Our Company
    • Our story
    • Our vision and strategy
    • Fibrotic lung diseases
    • CEO statement
    • Board of Directors
    • Management
    • Scientific Advisers
    • Contact
    • Work with us
  • Our focus areas
    • Mechanism of Action
    • Severe lung diseases
    • Role of the renin-angiotensin system
    • Role of the AT2 receptor
  • Our programs
    • Pipeline
Investors Investerare (SE)
  • Patients and families
    • Disease background
    • Patient story
    • Resources and patient organizations
    • Working with patient groups
    • Access policy
    • Our commitment
logo
Home / Investors / Corporate governance / Auditors
Overview Press releases
  • The share
    • Share monitor
    • Largest shareholders
    • Share issues
    • Share capital development
    • Analyst coverage
    • Listing prospectus
Financial reports Financial calendar Events & Presentations
  • Corporate governance
    • Corporate governance reports
    • General meeting
    • Nomination committeé
    • Board of Directors
    • Audit Committee
    • Remuneration Committee
    • Scientific committee
    • Management
    • Remuneration and incentives
    • Auditors
    • Scientific Advisers
    • Articles of association
Image bank Subscribe for press releases Investor Relations contact

Auditors

Ernst & Young AB
Parkgatan 49
401 82 Göteborg

Head auditor: Linda Sallander, auktorized auditor and partner

logo
Vicore Pharma’s offices

Kronhusgatan 11
411 05 Göteborg, Sweden

Kornhamnstorg 53
SE-111 27 Stockholm, Sweden

Agern Allé 5A
DK-2970 Hørsholm, Denmark

We'd love to hear from you!
Phone: +46 (0) 31 788 05 60 Mail: info@vicorepharma.com
Quick links
Contact Subscribe for press releases Privacy Policy Cookies